Novo Nordisk, the Danish pharmaceutical giant known for its innovative treatments for obesity and diabetes, is facing a major internal crisis. Several board members have resigned following tensions between the board of directors and the company’s main shareholder, the Novo Nordisk Foundation, according to CNBC, cited by News.ro.
Chairman Helge Lund, Vice-Chairman Henrik Poulsen, and most of the independent directors have stepped down after disagreements over the pace of leadership restructuring and the process of selecting a new CEO.
Read full article here: turnovernews.com
Read also: Norofert officially opens its new production facility in Brazil
Photo: AP News
UK
IT
ES
DE
FR
RO
PT
HU
